Tailor Bio

Tailor Bio is a Cambridge-based biotechnology company developing an AI-driven precision medicine platform for cancers with chromosomal instability, a genomic phenomenon present in over 80% of all cancers.

Founded from research originating at the Cancer Research UK Cambridge Institute, the company develops both therapeutic and diagnostic applications.

Pipeline includes a diagnostic test predicting doxorubicin response in high-grade serous ovarian cancer, developed in collaboration with Illumina and the University of Cambridge.